Published by Pure Lyf Telehealth | May 2026 | General educational information only
Medicinal cannabis has moved from the fringes of Australian healthcare to a legitimate, TGA-regulated clinical pathway — and a growing number of Australians with chronic conditions are asking their doctors about it for the first time.
This article is not a recommendation or endorsement of any specific treatment. It is educational information about how medicinal cannabis works in Australia, who it may be appropriate for, and how to access a proper clinical assessment through your GP. All treatment decisions must be made with a qualified medical practitioner who knows your individual health situation.
What is medicinal cannabis — and is it legal in Australia?
Yes — medicinal cannabis is legal in Australia when prescribed by a registered medical practitioner through the Therapeutic Goods Administration (TGA) framework.
Australia introduced legal access to medicinal cannabis in 2016. Since then, the number of approvals has grown substantially each year as more GPs become trained in prescribing and more clinical evidence emerges supporting its use in certain conditions.
Medicinal cannabis is not the same as recreational cannabis. It is a pharmaceutical-grade product manufactured to strict quality standards, prescribed for specific clinical indications, and dispensed by registered pharmacies. It requires a valid prescription from an AHPRA-registered doctor — there is no legal way to access it without one.
Who may be appropriate for a medicinal cannabis assessment?
Medicinal cannabis is not appropriate for everyone, and a GP assessment is the only way to determine whether it is right for you. That said, the conditions where the clinical evidence is strongest and where TGA approvals are most commonly granted include:
Chronic pain — particularly pain that has not responded adequately to conventional treatments. This includes musculoskeletal pain, neuropathic pain, and pain associated with conditions like arthritis, fibromyalgia, and spinal injuries.
Sleep disorders — difficulty falling or staying asleep, particularly when associated with an underlying condition such as chronic pain, anxiety, or PTSD. Poor sleep quality significantly affects quality of life and overall health outcomes.
Anxiety and stress-related conditions — including generalised anxiety disorder and PTSD, where conventional treatments have been insufficient or have caused significant side effects.
Palliative care — for patients managing pain, nausea, appetite loss, or distress in the context of a life-limiting illness. Medicinal cannabis is increasingly used in this setting both in Australia and internationally.
Neurological conditions — including certain forms of epilepsy, multiple sclerosis-related spasticity, and other conditions where evidence is emerging.
This list is not exhaustive and does not mean these conditions will automatically qualify. A GP must assess each individual’s full medical history, current medications, and clinical circumstances before determining whether medicinal cannabis is appropriate.
Medicinal cannabis in aged care — what the evidence says
Older Australians living in aged care or managing age-related chronic conditions represent one of the fastest-growing groups exploring medicinal cannabis — and for understandable reasons.
Chronic pain affects an estimated 60–80% of aged care residents, yet is frequently undertreated or managed with opioids and other medications that carry significant side effect burdens in elderly patients — including falls risk, cognitive effects, and dependency.
A growing body of published research is examining medicinal cannabis as an alternative or adjunct for pain management in older adults. Key findings from peer-reviewed literature include:
- A 2019 study published in the European Journal of Internal Medicine found that medicinal cannabis treatment in patients over 65 was associated with significant improvements in pain, sleep, and quality of life, with a manageable side effect profile.
- Research from Israel — which has one of the world’s most established medical cannabis programmes — has documented meaningful improvements in pain and quality of life in elderly patients, with many reducing or eliminating opioid use.
- Australian researchers have highlighted the potential for medicinal cannabis to reduce polypharmacy burden in older patients — the use of multiple medications simultaneously, which carries significant interaction and side effect risks.
This evidence does not mean medicinal cannabis is right for every aged care resident or older Australian. Age-related factors including cognitive status, medication interactions, and individual health profiles must be carefully assessed by a qualified GP. But it does mean the conversation is a legitimate and worthwhile one to have with a doctor.
Medicinal cannabis and NDIS participants
NDIS participants living with chronic pain, neurological conditions, anxiety, or other eligible conditions may also wish to explore whether a medicinal cannabis assessment is appropriate for them.
It is important to understand that medicinal cannabis is not funded by the NDIS. It is a health-related expense separate from NDIS supports. Participants would need to fund the cost of GP consultations and any prescribed medication themselves, or through Medicare where applicable.
If you are an NDIS participant considering a medicinal cannabis assessment, the appropriate first step is to speak with your existing GP or treating specialist. Your support coordinator can help you understand how a new health appointment fits within your overall support plan, but cannot make clinical recommendations about whether medicinal cannabis is appropriate for you.
What does a medicinal cannabis assessment involve?
Accessing medicinal cannabis in Australia involves a straightforward clinical process:
Step 1 — Initial consultation with a GP You speak with a registered GP who is trained in medicinal cannabis prescribing. The doctor takes a full medical history, reviews your current medications, discusses your symptoms and treatment history, and determines whether medicinal cannabis may be clinically appropriate.
Step 2 — TGA approval (where required) Depending on the product and indication, your GP may need to obtain approval from the TGA through the Special Access Scheme (SAS-B) or Authorised Prescriber pathway. This is a regulatory step handled by the doctor — not the patient.
Step 3 — Prescription and dispensing If approved, a prescription is issued. This can be dispensed at a registered pharmacy, including through mail-order dispensing services for patients in regional or remote areas.
Step 4 — Follow-up and review Ongoing follow-up appointments allow the doctor to monitor your response, adjust dosage if needed, and ensure the treatment continues to be appropriate. These follow-up consultations are an important part of safe ongoing care.
The entire process can be completed via telehealth — no in-person visit is required. This makes it accessible for Australians who have difficulty travelling, including aged care residents and people with mobility limitations.
What does it cost?
Costs vary depending on the provider, the product prescribed, and the frequency of follow-up appointments. As a general guide:
- Initial consultation: $49–$150 depending on the provider
- Follow-up consultations: $19–$80
- Product cost: varies significantly by formulation and dosage — typically $100–$400 per month depending on what is prescribed
Medicinal cannabis products are not currently subsidised by the Pharmaceutical Benefits Scheme (PBS), meaning patients pay the full cost of the medication. This is an important consideration for people on fixed incomes or pension payments.
How to access a GP assessment
If you or someone you care for would like to explore whether medicinal cannabis is appropriate, the right first step is a conversation with a qualified GP.
Pure Lyf Telehealth offers TGA-compliant medicinal cannabis assessments conducted by Dr Jonathan Chua, a registered GP with experience in medicinal cannabis prescribing. Appointments are conducted entirely via telehealth — from the comfort of your own home or care setting.
To book an initial assessment or to ask a question before booking, visit: [www.purelyf.com.au]
Bringing a list of your current medications and a summary of your medical history to the appointment will help Dr Chua conduct a thorough assessment.
Important information
This article has been prepared for general educational purposes only. It does not constitute medical advice and should not be relied upon as a substitute for professional medical consultation. Individual circumstances vary significantly and only a qualified medical practitioner who knows your full health history can advise on whether medicinal cannabis is appropriate for you.
Medicinal cannabis is a prescription medicine regulated by the Therapeutic Goods Administration (TGA). It cannot be legally accessed without a valid prescription from an AHPRA-registered doctor.
References to clinical research in this article are provided for general educational context. They do not constitute endorsement of medicinal cannabis as a treatment for any specific condition.
For organisations sharing this content
Disclosure notice for third-party sharing: Organisations sharing or linking to this article who have directors, staff, or owners with a financial interest in Pure Lyf Pty Ltd should disclose that interest clearly when sharing this content. This ensures transparency for readers and compliance with NDIS Code of Conduct obligations regarding conflicts of interest.
Pure Lyf Telehealth | TGA-compliant medicinal cannabis assessments | [www.purelyf.com.au]
This content complies with TGA advertising guidelines for telehealth services. No specific medicinal cannabis products are named or promoted. All clinical decisions are made by AHPRA-registered medical practitioners.
